Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch
Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q3-2020 (July – September 2020), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/SIGNIFICANT EVENTS IN Q3-2020 · First commercial scale manufacturing of Mangoral · Proceeds from directed share issue received in the beginning of July SIGNIFICANT EVENTS AFTER THE PERIOD · In October, the estimate of the addressable market for Mangoral was upgraded to $500-600 million annually (previously $350-500 million) · In November,